Log in

Relevant bibliographies by topics / Immunoglobulin G/pharmacology / Journal articles

To see the other types of publications on this topic, follow the link: Immunoglobulin G/pharmacology.

Journal articles on the topic 'Immunoglobulin G/pharmacology'

Author: Grafiati

Published: 2 June 2025

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Immunoglobulin G/pharmacology.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Красавцев, Е. Л., and М. В. Подоляко. "Detection Rate of Immunoglobulins G to Toxocar Antigens in the Republic of Belarus." Педиатрия. Восточная Европа, no. 3 (November 3, 2022): 319–24. http://dx.doi.org/10.34883/pi.2022.10.3.003.

Full text

Abstract:

Цель. Изучить частоту выявления иммуноглобулинов G к антигенам токсокар у детей в различных регионах Республики Беларусь, различного возраста, пола.Материалы и методы. Анализ на иммуноглобулины G к антигенам токсокар был взят у 11 541 ребенка. Сравнение частоты выявления иммуноглобулинов G к антигенам токсокар у детей, проживающих в различных регионах Республики Беларусь, различного пола, возраста было произведено методами непараметрической статистики (таблицы 2×2, критерий χ2).Результаты. В результате исследования 11 541 ребенка иммуноглобулины G к антигенам токсокар были выявлены у 1153 чело

APA, Harvard, Vancouver, ISO, and other styles

2

Liu, Di, Jing You, Yexin Liu, et al. "Serum immunoglobulin G provides early risk prediction in immunoglobulin A nephropathy." International Immunopharmacology 66 (January 2019): 13–18. http://dx.doi.org/10.1016/j.intimp.2018.10.044.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Jurhar-Pavlova, Maja, Aleksandar Petlichkovski, Dejan Trajkov, et al. "Influence of the elevated ambient temperature on immunoglobulin G and immunoglobulin G subclasses in sera of Wistar rats." Vojnosanitetski pregled 60, no. 6 (2003): 657–61. http://dx.doi.org/10.2298/vsp0306657j.

Full text

Abstract:

The aim of our research was to examine changes in the immune system of the rats influenced by the elevated ambient temperature. Male Wistar rats were divided, into 2 groups and housed at 20 ? 2?C (n=64, control group) and 35 ? 1?C (n=74, experimental group), during precise timing of 1, 4, 7, 14, 21, and 30 days. All the animals were given food and water ad libitum, and were lighted during 12 hours per day. We have measured IgG, IgG1, IgG2a, IgG2b and IgG2c. The obtained results showed significant elevation in the level of IgG after 4 and 7 days (+32%), IgG2a after 7th (+88%), 14th and 21nd day

APA, Harvard, Vancouver, ISO, and other styles

4

Kinoshita, Makiko, and A. Catharine Ross. "Quantitative Analysis of Immunoglobulin G Subclasses in the Rat." Journal of Immunoassay 14, no. 3 (1993): 149–66. http://dx.doi.org/10.1080/15321819308019846.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Buttmann, Mathias, Srini Kaveri, and Hans-Peter Hartung. "Polyclonal immunoglobulin G for autoimmune demyelinating nervous system disorders." Trends in Pharmacological Sciences 34, no. 8 (2013): 445–57. http://dx.doi.org/10.1016/j.tips.2013.05.009.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Voltersvik, Pål, Grethe Albrektsen, Elling Ulvestad, Anne Dyrhol-Riise, Birger Sørensen, and Birgitta Åsjö. "Changes in Immunoglobulin Isotypes and Immunoglobulin G (IgG) Subclasses During Highly Active Antiretroviral Therapy." JAIDS Journal of Acquired Immune Deficiency Syndromes 34, no. 4 (2003): 358–67. http://dx.doi.org/10.1097/00126334-200312010-00002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Miura, Yoko, Masafumi Uematsu, Mugen Teshima, et al. "Injection Site and Pharmacokinetics After Intravitreal Injection of Immunoglobulin G." Journal of Ocular Pharmacology and Therapeutics 27, no. 1 (2011): 35–41. http://dx.doi.org/10.1089/jop.2010.0112.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Ghosh, Asish Kumar, Olfert Landt, Mahmuda Yeasmin, et al. "Clinical Presentation of COVID-19 and Antibody Responses in Bangladeshi Patients Infected with the Delta or Omicron Variants of SARS-CoV-2." Vaccines 10, no. 11 (2022): 1959. http://dx.doi.org/10.3390/vaccines10111959.

Full text

Abstract:

The clinical presentation of COVID-19 and the specific antibody responses associated with SARS-CoV-2 variants have not been investigated during the emergence of Omicron variants in Bangladesh. The Delta and Omicron variants were identified by post-PCR melting curve analysis of the spike (S) protein receptor binding domain amplicons. Anti-S-protein immunoglobulin-G anti-nucleocapsid (N)-protein immunoglobulin-G and immunoglobulin-A levels were measured by ELISA. The Delta variant was found in 40 out of 40 (100%) SARS-CoV-2 RT-PCR positive COVID-19 patients between 13 September and 23 October 20

APA, Harvard, Vancouver, ISO, and other styles

9

JARLØV, A. E., P. MUNKHOLM, P. NORDBLAD SCHMIDT, E. LANGHOLZ, B. FABER VESTERGAARD, and R. MøLSKOV BECH. "Treatment of active distal ulcerative colitis with immunoglobulin G enemas." Alimentary Pharmacology & Therapeutics 7, no. 5 (2007): 561–65. http://dx.doi.org/10.1111/j.1365-2036.1993.tb00133.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Dunsmore, Kimberly P. "Intravenous Immunoglobulin G Therapy in Fetal and Neonatal Alloimmune Thrombocytopenia." BioDrugs 8, no. 4 (1997): 265–72. http://dx.doi.org/10.2165/00063030-199708040-00003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Akatsuka, Masayuki, Yoshiki Masuda, Hiroomi Tatsumi, and Tomoko Sonoda. "Efficacy of Intravenous Immunoglobulin Therapy for Patients With Sepsis and Low Immunoglobulin G Levels: A Single-Center Retrospective Study." Clinical Therapeutics 44, no. 2 (2022): 295–303. http://dx.doi.org/10.1016/j.clinthera.2021.12.008.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Markovic-Sovtic, Gordana, Borisav Jankovic, Zorica Rakonjac, Jelena Martic, and Katarina Pejic. "Use of intravenous immunoglobulin in neonates with haemolytic disease and immune thrombocytopenia." Vojnosanitetski pregled 70, no. 11 (2013): 1029–33. http://dx.doi.org/10.2298/vsp1311029m.

Full text

Abstract:

Background/Aim. Intravenous immunoglobulin is a blood product made of human polyclonal immunoglobulin G. The mode of action of intravenous immunoglobulin is very complex. It is indicated in treatment of neonatal immune thrombocytopenia and haemolytic disease of the newborn. The aim of the study was to present our experience in the use of intravenous immunoglobulin in a group of term neonates. Methods. We analysed all relevant clinical and laboratory data of 23 neonates who recieved intravenous immunoglobulin during their hospitalization in Neonatal Intensive Care Unit of Mother and Child Healt

APA, Harvard, Vancouver, ISO, and other styles

13

Sechan, Ferdyansyah, Katherine Loens, Herman Goossens, Margareta Ieven, and Lia van der Hoek. "Endemic Human Coronavirus-Specific Nasal Immunoglobulin A and Serum Immunoglobulin G Dynamics in Lower Respiratory Tract Infections." Vaccines 12, no. 1 (2024): 90. http://dx.doi.org/10.3390/vaccines12010090.

Full text

Abstract:

Endemic human coronaviruses (HCoV) NL63, 229E, OC43, and HKU1 cause respiratory infection. Following infection, a virus-specific serum antibody rise is usually observed, coinciding with recovery. In some cases, an infection is not accompanied by an immunoglobulin G (IgG) antibody rise in serum in the first month after HCoV infection, even though the infection has cleared in that month and the patient has recovered. We investigated the possible role of nasal immunoglobulin A (IgA). We measured spike (S) and nucleocapsid (N)-specific nasal IgA during and after an HCoV lower respiratory tract inf

APA, Harvard, Vancouver, ISO, and other styles

14

Li, Hong, Yanhui Lu, Longzhu Piao, et al. "Folate-Immunoglobulin G as an Anticancer Therapeutic Antibody." Bioconjugate Chemistry 21, no. 5 (2010): 961–68. http://dx.doi.org/10.1021/bc900545h.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Corona, Alberto, Giuseppe Richini, Sara Simoncini, et al. "Treating Critically Ill Patients Experiencing SARS-CoV-2 Severe Infection with Ig-M and Ig-A Enriched Ig-G Infusion." Antibiotics 10, no. 8 (2021): 930. http://dx.doi.org/10.3390/antibiotics10080930.

Full text

Abstract:

SARS-CoV-2 in patients who need intensive care unit (ICU) is associated with a mortality rate ranging from 10 to 40–45%, with an increase in morbidity and mortality in presence of sepsis. We hypothesized that IgM and IgA enriched immunoglobulin G may support the sepsis-related phase improving patient outcome. We conducted a retrospective case–control study on 47 consecutive patients admitted to our ICU. At the time of admission, patients received anticoagulants (heparin sodium) together with the standard supportive treatment. We decided to add IgM and IgA enriched immunoglobulin G to the stand

APA, Harvard, Vancouver, ISO, and other styles

16

&NA;. "Intravenous immunoglobulin G makes antenatal therapy possible in neonatal alloimmune thrombocytopenia." Drugs & Therapy Perspectives 11, no. 10 (1998): 6–8. http://dx.doi.org/10.2165/00042310-199811100-00002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Girkontaite, Irute, Margarita Leckiene, and Mykolas Mauricas. "Immunochemical Study of Human Immunoglobulin G Fc Region." Cancer Biotherapy and Radiopharmaceuticals 11, no. 1 (1996): 87–96. http://dx.doi.org/10.1089/cbr.1996.11.87.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Winward, Doreen Bianchi, and Mary T. Brophy. "Acute Renal Failure After Administration of Intravenous Immunoglobulin: Review of the Literature and Case Report." Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 15, no. 6 (1995): 765–72. http://dx.doi.org/10.1002/j.1875-9114.1995.tb02894.x.

Full text

Abstract:

Within in last 7 years the literature has published several reports of acute renal failure after the administration of intravenous immunoglobulin. Review of these cases finds that all occurrences in the United States except one involved a sucrose‐containing immunoglobulin preparation, leading to the suspicion that sucrose may be the cause of the renal failure. Further investigation found that approximately 50 years ago, when sucrose was used as an osmotic diuretic, investigators reported acute renal failure in humans after intravenous infusions of 50 g or more. A patient at our institution dev

APA, Harvard, Vancouver, ISO, and other styles

19

Drabick, Joseph J., Apurba K. Bhattacharjee, David L. Hoover, et al. "Covalent Polymyxin B Conjugate with Human Immunoglobulin G as an Antiendotoxin Reagent." Antimicrobial Agents and Chemotherapy 42, no. 3 (1998): 583–88. http://dx.doi.org/10.1128/aac.42.3.583.

Full text

Abstract:

ABSTRACT Polymyxin B (PMB) is a cyclic decapeptide antibiotic which also binds and neutralizes endotoxin. Unfortunately, PMB can be considerably nephrotoxic at clinically utilized doses, thereby limiting its utility as a therapeutic antiendotoxin reagent. We sought to change the pharmacokinetics and toxicity profile of PMB by covalently linking it to a human immunoglobulin G (IgG) carrier. Conjugates of PMB with IgG were prepared by EDAC [1-ethyl-3-(3-dimethylaminopropyl) carbodiimide]-mediated amide formation. Analysis by dot enzyme-linked immunosorbent assay with an anti-PMB monoclonal antib

APA, Harvard, Vancouver, ISO, and other styles

20

Nikolac Perkovic, Matea, Maja Pucic Bakovic, Jasminka Kristic, et al. "The association between galactosylation of immunoglobulin G and body mass index." Progress in Neuro-Psychopharmacology and Biological Psychiatry 48 (January 2014): 20–25. http://dx.doi.org/10.1016/j.pnpbp.2013.08.014.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Anwar, Ali, Syed Uzair Ali Shah, Muhammad Naeem Rajput, Saeed Ahmed Soomro, and Atique Ahmed Behan. "Effects of Moringa oleifera leaf meal supplementation on growth performance and blood profiles of cattle heifers." World Journal of Biology and Biotechnology 9, no. 1 (2024): 25. http://dx.doi.org/10.33865/wjb.009.01.1183.

Full text

Abstract:

To evaluate the impact of dietary inclusion of Moringa oleifera leaf meal (MOLM) on the growth performance, body conformation, and blood biochemistry of intensively managed cattle heifers, a total of 12 heifers were randomly selected and divided into two groups viz. group-CON (basal diet) and group-MOLM (basal diet + 10% Moringa oleifera leaf meal). Results indicate that significantly higher feed intake was observed in the MOLM group. The heifers supplemented with MOLM were having significantly improved body weight, body height, body length and heart girth compared to the heifers in CON group.

APA, Harvard, Vancouver, ISO, and other styles

22

Rosselli, Jennifer L., Stacey M. Thacker, Julie P. Karpinski, and Katherine A. Petkewicz. "Treatment of IgA Nephropathy: An Update." Annals of Pharmacotherapy 45, no. 10 (2011): 1284–96. http://dx.doi.org/10.1345/aph.1q122.

Full text

Abstract:

Objective: To review current literature regarding treatment options for immunoglobulin A nephropathy (IgAN). Data Sources: A MEDLINE search was performed using the terms IgA nephropathy, Berger's disease, immunoglobulin A nephropathy, angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, fish oil, omega-3 fatty acids, statins. hydroxymethylglutaryl-CoA reductase Inhibitors, immunosuppressive therapy, corticosteroids, mycophenolate mofetil, cyclophosphamide, cyclosporine, azathioprine, leflunomide, antiplatelets, anticoagulants, vitamin E, infliximab, calcitriol, and intra

APA, Harvard, Vancouver, ISO, and other styles

23

Więsik-Szewczyk, Ewa, Aleksandra Kucharczyk, and Karina Jahnz-Różyk. "Current treatment options with immunoglobulin G for adult patients with primary immunodeficiency disease in Poland." Journal of Health Policy & Outcomes Research, no. 2 (December 31, 2014): 42–49. http://dx.doi.org/10.7365/jhpor.2014.2.5.

Full text

Abstract:

Polyclonal immunoglobulin G life-long replacement is a corner stone therapy in patients with primary antibodies deficiency. The evidence of safety and effectiveness of IgG in PAD are strongly documented for reduction and protection for serious infections. There are still limited data for deletion from long term complications as progression of chronic lung diseases, bronchiectasis and damage. Nowadays accelerated progress in IgG products modulation and ways of administration allows for adjustment of this chronic treatment for patients needs and preferences, improving the patients’ compliances a

APA, Harvard, Vancouver, ISO, and other styles

24

Kimberly, Robert P., Jane E. Salmon, and Jeffrey C. Edberg. "Receptors for immunoglobulin g molecular diversity and implications for disease." Arthritis & Rheumatism 38, no. 3 (1995): 306–14. http://dx.doi.org/10.1002/art.1780380303.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Xuan, D., D. P. Nicolau, P. R. Tessier, L. Bow, R. Quintiliani, and C. H. Nightingale. "In vitro reduction of endotoxin concentrations with the 5S fragment of immunoglobulin G." Antimicrobial Agents and Chemotherapy 41, no. 7 (1997): 1512–16. http://dx.doi.org/10.1128/aac.41.7.1512.

Full text

Abstract:

Endotoxin has long been implicated as an inducer for the development and progression of gram-negative sepsis. Accordingly, antiendotoxin therapy has been considered one of the major targets for the treatment of sepsis. To investigate the influence of a human immunoglobulin G (IgG) derivative, the 5S fragment of IgG (5S-IgG; Gamma-Venin, Centeon Pharma GmbH, Frankfurt-Niederrad, Germany), on endotoxin release during bacterial proliferation and under antibiotic bactericidal action, time-kill studies were performed by using Escherichia coli ATCC 25922 starting inocula of 10(3), 10(5), and 10(7) C

APA, Harvard, Vancouver, ISO, and other styles

26

SHIBAGUCHI, Hirotomo, Tomoka YAMAMOTO, Masahide KUROKI, and Koujiro FUTAGAMI. "Measurement and Assessment of Cytomegalovirus of Immunoglobulin (Ig) G Titer in Preparations." YAKUGAKU ZASSHI 130, no. 7 (2010): 977–82. http://dx.doi.org/10.1248/yakushi.130.977.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Ahn, Sang K., Yong K. Shin, Hee J. Kang, Eun S. Han, and Chung S. Lee. "Effects of protein kinase inhibitors on the stimulated neutrophil responses by degraded immunoglobulin G." European Journal of Pharmacology 306, no. 1-3 (1996): 175–80. http://dx.doi.org/10.1016/0014-2999(96)00097-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Christ, Torsten, Esther Adolph, Stefan Schindelhauer, et al. "Effects of Immunoglobulin G from Patients with Dilated Cardiomyopathy on Rat Cardiomyocytes." Basic Clinical Pharmacology Toxicology 96, no. 6 (2005): 445–52. http://dx.doi.org/10.1111/j.1742-7843.2005.pto_96607.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Andresen, Irmgard, John M. Kovarik, Martin Spycher, and Reinhard Bolli. "Product Equivalence Study Comparing the Tolerability, Pharmacokinetics, and Pharmacodynamics of Various Human Immunoglobulin-G Formulations." Journal of Clinical Pharmacology 40, no. 7 (2000): 722–30. http://dx.doi.org/10.1177/00912700022009477.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Hornby, Pamela J., Philip R. Cooper, Connie Kliwinski, et al. "Human and Non-Human Primate Intestinal FcRn Expression and Immunoglobulin G Transcytosis." Pharmaceutical Research 31, no. 4 (2013): 908–22. http://dx.doi.org/10.1007/s11095-013-1212-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Huda Sahib Al-Rawazq, Luay Ibraheem Al-Rawi, and Riyadh Abdul-R Al-Zubaidy. "Seroprevalence of celiac disease among children in Baghdad, Iraq." International Journal of Research in Pharmaceutical Sciences 12, no. 2 (2021): 954–57. http://dx.doi.org/10.26452/ijrps.v12i2.4609.

Full text

Abstract:

Celiac disease (CD) represents A unique disorders in which consumption of a food ingredient namely gluten-containing grains (wheat, rye, barley) in combination with genetic susceptibility is fundamental for the development of an a guilefully evolving autoimmune reaction influence the gut and other organs. The present study determines the celiac disease among suspected children. From special the laboratory for Pathogenesis Analyses in Baghdad 100 blood children samples was collected during the period from 1st March 2018 till the 31 th of July 2018, analyzed by two serological test which were An

APA, Harvard, Vancouver, ISO, and other styles

32

Huda Sahib Al-Rawazq, Luay Ibraheem Al-Rawi, and Riyadh Abdul-R Al-Zubaidy. "Seroprevalence of celiac disease among children in Baghdad, Iraq." International Journal of Research in Pharmaceutical Sciences 11, SPL4 (2020): 2609–12. http://dx.doi.org/10.26452/ijrps.v11ispl4.4521.

Full text

Abstract:

Celiac disease (CD) represents A unique disorders in which consumption of a food ingredient namely gluten-containing grains (wheat, rye, barley) in combination with genetic susceptibility is fundamental for the development of an a guilefully evolving autoimmune reaction influence the gut and other organs. The present study determines the celiac disease among suspected children. From special the laboratory for Pathogenesis Analyses in Baghdad 100 blood children samples was collected during the period from 1st March 2018 till the 31 th of July 2018, analyzed by two serological test which were An

APA, Harvard, Vancouver, ISO, and other styles

33

Lindsay, Christine A., Ken Dang, James M. Adams, Ching Nan Ou, and Carol J. Baker. "Stability and Activity of Intravenous Immunoglobulin with Neonatal Dextrose and Total Parenteral Nutrient Solutions." Annals of Pharmacotherapy 28, no. 9 (1994): 1014–17. http://dx.doi.org/10.1177/106002809402800902.

Full text

Abstract:

OBJECTIVE: To determine in vitro the compatibility of reconstituted intravenous immunoglobulin (IVIG) (Gammagard, Baxter-Hyland) with five different neonatal and pediatric intravenous solutions in Viaflex polyvinyl chloride bags. DESIGN: In vitro compatibility study. INTERVENTIONS: Samples were taken at time=0, 10, 30, 60, 90, and 120 minutes and at 4, 8, 12, and 24 hours and assayed for total immunoglobulin G content and antibodies to hepatitis B surface antigen. Type III group B Streptococcus (GBS) and opsonic activity for type III GBS were analyzed at time=0, 60, and 120 minutes and 12 and

APA, Harvard, Vancouver, ISO, and other styles

34

Li, Zhaoyang, Kristin Follman, Ed Freshwater, Frank Engler, and Leman Yel. "Integrated population pharmacokinetics of immunoglobulin G following intravenous or subcutaneous administration of various immunoglobulin products in patients with primary immunodeficiencies." International Immunopharmacology 113 (December 2022): 109331. http://dx.doi.org/10.1016/j.intimp.2022.109331.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Li, Zhaoyang, Kristin Follman, Ed Freshwater, Frank Engler, and Leman Yel. "Population pharmacokinetics of immunoglobulin G after intravenous, subcutaneous, or hyaluronidase-facilitated subcutaneous administration in immunoglobulin-naive patients with primary immunodeficiencies." International Immunopharmacology 128 (February 2024): 111447. http://dx.doi.org/10.1016/j.intimp.2023.111447.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Lee, Jian Lynn, Noraida Mohamed Shah, Mohd Makmor-Bakry, Farida Islahudin, Hamidah Alias, and Shamin Mohd Saffian. "A systematic review of population pharmacokinetic analyses of polyclonal immunoglobulin G therapy." International Immunopharmacology 97 (August 2021): 107721. http://dx.doi.org/10.1016/j.intimp.2021.107721.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Muratsugu, Makoto, Ayaka Yazawa, Sami Fujiwara, Satsuki Nishida, and Toru Fukui. "Quantitation of Biotin-Binding Immunoglobulins G, A, and M in Human Sera Using F(ab′)2Anti-human Immunoglobulin-Coated Microplates." Biological & Pharmaceutical Bulletin 31, no. 3 (2008): 507–10. http://dx.doi.org/10.1248/bpb.31.507.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Kruljec, Nika, Peter Molek, Vesna Hodnik, Gregor Anderluh, and Tomaž Bratkovič. "Development and Characterization of Peptide Ligands of Immunoglobulin G Fc Region." Bioconjugate Chemistry 29, no. 8 (2018): 2763–75. http://dx.doi.org/10.1021/acs.bioconjchem.8b00395.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Li, Danqi, Yuchen Lou, Yamin Zhang, Si Liu, Jun Li, and Juan Tao. "Sialylated immunoglobulin G: a promising diagnostic and therapeutic strategy for autoimmune diseases." Theranostics 11, no. 11 (2021): 5430–46. http://dx.doi.org/10.7150/thno.53961.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Lavrnic, Dragana, Marija Romic, Aleksandra Kacar, et al. "High doses of immunoglobulin g in the therapy for severe forms of myasthenia gravis and Guillain-Barré syndrome." Vojnosanitetski pregled 63, no. 1 (2006): 37–42. http://dx.doi.org/10.2298/vsp0601037l.

Full text

Abstract:

Background/Aim. High doses of immunoglobulin G (IVIG) have been recognized as a very important therapeutic modality in the treatment of neurological diseases. The aim of this report was to present our experience in the treatment of severe forms of myasthenia gravis (MG) and Guillain-Barr? syndrome (GBS). Methods. We analyzed the efficacy and safety of immunoglobulin G therapy in 53 patients with severe forms of myasthenia gravis, and 27 patients with very severe forms of Guillain-Barr? syndrome. Results. At the end of the follow-up period, a significant improvement was noticed in 47 out of 53

APA, Harvard, Vancouver, ISO, and other styles

41

Balkovic, Edward S., James A. Florack, and Howard R. Six. "Immunoglobulin G subclass antibody responses of mice to influenza virus antigens given in different forms." Antiviral Research 8, no. 3 (1987): 151–60. http://dx.doi.org/10.1016/0166-3542(87)90068-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Cn, Hemalatha, Vijey Aanandhi M, and Vijey Aanandhi M. "G-QUADRUPLEX LIGANDS AS STABILIZER TARGETING TELOMERASE ENZYME AS ANTI CANCER AGENTS." Asian Journal of Pharmaceutical and Clinical Research 10, no. 8 (2017): 50. http://dx.doi.org/10.22159/ajpcr.2017.v10i8.19797.

Full text

Abstract:

The human telomere stabilization with G-Quadruplex DNA tends to induce apoptosis. The molecular target of telomere cascade with a rigid molecular may show efficacious to treat cancer. The study of intercalation to human telomeric DNA with proposed ligand can be evaluated by the help of biophysical studies and biological studies. G-Quadruplex is one of the key epigenetic episodes of eukaryotes and prokaryotes, generally found in the telomeric end region, immunoglobulin switch recombination and the lagging strand of the DNA. These chemotherapeutic advances are not enough to maintain a life expec

APA, Harvard, Vancouver, ISO, and other styles

43

MIMURA, Tsutomu, Masaaki ITOH, Tetsuya SUGIYAMA, et al. "Studies on Pharmacological Activation of Human Immunoglobulin G by Chemical Modification and Active Subfragments. X. Effect of Carboxamidemethylated Fc Fragment (CM-Fc) from Human Immunoglobulin G on Delayed Type Hypersensitivity." Biological & Pharmaceutical Bulletin 16, no. 9 (1993): 858–60. http://dx.doi.org/10.1248/bpb.16.858.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

MIMURA, Tsutomu, Masaaki ITOH, Tetsuya SUGIYAMA, et al. "Studies on Pharmacological Activation of Human Immunoglobulin G by Chemical Modification and Active Subfragments. XII. Effect of Carboxamidemethylated Fc Fragment (CM-Fc) from Human Immunoglobulin G on Mixed Lymphocyte Reaction." Biological & Pharmaceutical Bulletin 17, no. 3 (1994): 411–14. http://dx.doi.org/10.1248/bpb.17.411.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Mushcab, Hayat, Jaffar A. Al-Tawfiq, Amani Babgi, et al. "Longevity of Immunoglobulin-G Antibody Response Against Nucleocapsid Protein Against SARS-CoV-2 Among Healthcare Workers." Infection and Drug Resistance Volume 16 (May 2023): 3407–16. http://dx.doi.org/10.2147/idr.s400365.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Liu, Di, Qihuan Li, Jing Dong, et al. "The Association Between Normal BMI With Central Adiposity And Proinflammatory Potential Immunoglobulin G N-Glycosylation." Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy Volume 12 (November 2019): 2373–85. http://dx.doi.org/10.2147/dmso.s216318.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Paula, Nigella, Marcelo Conzentino, Ana Gonçalves, et al. "Population-Based Analysis of the Immunoglobulin G Response to Different COVID-19 Vaccines in Brazil." Vaccines 11, no. 1 (2022): 21. http://dx.doi.org/10.3390/vaccines11010021.

Full text

Abstract:

(1) Background: COVID-19 vaccination in Brazil has been performed mostly with CoronaVac (Sinovac), ChAdOx1-S (AstraZeneca-University of Oxford) and BNT162b2 (Pfizer-BioNTech) vaccines. The titers of IgG antibodies reactive to the SARS-CoV-2 spike protein correlate with vaccine efficacy. Studies comparing vaccine immunogenicity in a real-world scenario are lacking. (2) Methods: We performed a population-based study to analyze the immunoglobulin G response to different COVID-19 vaccines. Citizens older than 18 years (n = 2376) provided personal data, a self-declaration of any previous COVID-19 p

APA, Harvard, Vancouver, ISO, and other styles

48

He, Qing, Yejian Wu, Shuiping Hou, Lei Luo, and Zhoubin Zhang. "Seroprevalence of Diphtheria and Tetanus Immunoglobulin G among the General Health Population in Guangzhou, China." Vaccines 12, no. 4 (2024): 381. http://dx.doi.org/10.3390/vaccines12040381.

Full text

Abstract:

A seroepidemiological study was conducted in 2018 to assess diphtheria and tetanus antibodies in Guangzhou, China. Diphtheria and tetanus antibody concentrations were measured with an enzyme-linked immunosorbent assay. A total of 715 subjects were enrolled in the study. The overall diphtheria and tetanus toxoid IgG-specific antibody levels were 0.126 IU/mL (95% CI: 0.115, 0.137) and 0.210 IU/mL (95% CI: 0.185, 0.240), respectively; the overall positivity rate was 61.82% (95% CI: 58.14, 65.39) and 71.61% (95% CI: 68.3, 74.92), respectively. The diphtheria and tetanus antibody concentration was

APA, Harvard, Vancouver, ISO, and other styles

49

Salmon, Jane E., and Luminita Pricop. "Human receptors for immunoglobulin G: Key elements in the pathogenesis of rheumatic disease." Arthritis & Rheumatism 44, no. 4 (2001): 739–50. http://dx.doi.org/10.1002/1529-0131(200104)44:4<739::aid-anr129>3.0.co;2-o.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Okuda, Sachio, Shintaro Kamei, and Takumi Sasaki. "Immunoglobulin G Enhances Generation of Inducible T Regulatory Cells and Increases Their Regulatory Function." Biological and Pharmaceutical Bulletin 41, no. 12 (2018): 1830–36. http://dx.doi.org/10.1248/bpb.b18-00548.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!